Special Issue

Small Molecules as Antimicrobials 2022

Message from the Guest Editor

The World Health Organization (WHO) has announced antimicrobial resistance (AMR) as a major threat to public health. The rapid development and spread of new resistance mechanisms has made many antimicrobials useless in treating clinically ill patients. Even medical procedures such as major surgery, organ transplantation, and cancer chemotherapy have become very risky in the absence of effective antimicrobials for the prevention and treatment of infections. Therefore, there is an urgent need for new, better, and more effective antimicrobials. We invite authors to submit original research and review articles related to up-to-date and ongoing research focusing on the development and evaluation of potential new antimicrobial agents, as well as on the investigation of improved delivery protocols of both existing and new antimicrobial agents. Potential topics include but are not limited to:

- Development and testing of novel and effective antimicrobial agents;
- Antimicrobial agents active against drug-resistant forms:
- Recent advances in antimicrobial drug delivery.

Guest Editor

Dr. Poce Giovanna

Department of Chemistry and Technology of Drugs (DCTF), Sapienza University of Rome, Rome, Italy

Deadline for manuscript submissions

closed (15 April 2023)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/140148

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

